

July 19, 2024

Perseus Proteomics, Inc.

President & CEO: Takuya Yokokawa

e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)

### **Announcement of Acceptance of PPMX-T002 Research Results Presentation at EANM'24 Annual Congress**

Perseus Proteomics Inc. ("the Company") is pleased to announce that the research results of PPMX-T002, a radioisotope labelled antibody under development led by the Company, has been accepted for presentation at the EANM (European Association of Nuclear Medicine)'24 in Hamburg, Germany.

Title: Preclinical evaluation of Cadherin 3 (CDH3)-targeted alpha radiopharmaceutical therapy,  $^{225}\text{Ac}$ -PPMX-T002 for the treatment of solid cancer

Date: October 19 – 23, 2024

Author : S. Hagiwara\*, M. Kajita\*\*, K. Orihara\*\*, Y. Funase\*\*, K. Suzuki\*\*, S. Usuda\*\*\*, A. Nambu\*\*\*, H. Haba\*\*\*

\*Perseus Proteomics Inc., \*\* PDRadiopharma Inc., \*\*\*RIKEN

e-poster session No.: EP-04

e-poster No. : EP-0089

PPMX-T002 is a radioisotope labelled antibody against cadherin 3 (CDH3), which is highly expressed on solid tumors including head and neck, ovarian, pancreatic and lung cancers. The Company has been developing the antibody under a strategy to change the radioisotope from Yttrium 90 ( $^{90}\text{Y}$ ), a beta emitter, to Actinium 225 ( $^{225}\text{Ac}$ ), an alpha emitter. In the animal experiment using a mouse with human pancreatic cancer cells transplanted, it was shown that  $^{225}\text{Ac}$ -labelled antibody exhibited higher efficacy compared with  $^{90}\text{Y}$ -labelled antibody. At the annual congress, the Company will give a poster presentation of high anti-tumor efficacy and the potential human clinical application.

END